Related Experiment Video
Updated: Nov 16, 2025
Ultrasound Imaging-guided Intracardiac Injection to Develop a Mouse Model of Breast Cancer Brain Metastases Followed by Longitudinal MRI
Published on: March 6, 2014
[Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases]
1Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Abstract:
Brain metastases are the major cause of adult malignant nervous system tumors. For this part of population, treatment options are limited and the prognosis is poor. In recent years, immunotherapy based on inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death receptor ligand 1 (PD-L1), have brought innovation to the treatment of malignant tumors. Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC). Encouraging results have suggested that ICIs could be active in selected advanced NSCLC brain metastases with driver-negative patients. However, for patients with brain metastases, not only the corresponding clinical data are limited, but also the evaluation of its efficacy lacks a unified standard. This article aims to review the relevant efficacy evaluation standards and their application in clinical researches, compare the similarities and differences, and look forward to future trends. .
Insights
Immune checkpoint inhibitors (ICIs) show promise for non-small cell lung cancer (NSCLC) brain metastases. This review examines current efficacy evaluation standards for ICIs in NSCLC brain metastases, highlighting limited data and the need for unified assessment methods.
Area of Science:
- Neuro-oncology
- Medical oncology
- Immunotherapy
Background:
- Brain metastases are a leading cause of adult malignant nervous system tumors with limited treatment options and poor prognosis.
- Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein 1 (PD-1) and programmed cell death receptor ligand 1 (PD-L1), have transformed malignant tumor treatment.
- ICIs have shown revolutionary success in advanced non-small cell lung cancer (NSCLC), with emerging data suggesting activity in selected NSCLC brain metastases.
Purpose of the Study:
- To review current efficacy evaluation standards for ICIs in NSCLC brain metastases.
- To compare the similarities and differences of these evaluation standards.
- To discuss future trends in assessing ICI efficacy for this patient population.
Main Methods:
- Literature review of clinical studies evaluating ICIs in NSCLC brain metastases.
- Analysis of established and emerging efficacy evaluation criteria.
- Comparative assessment of different assessment methodologies.
Main Results:
- Limited clinical data currently exists for ICI treatment in NSCLC brain metastases.
- A lack of unified standards complicates the evaluation of ICI efficacy in this setting.
- Existing standards show variations in application and interpretation across studies.
Conclusions:
- Standardized efficacy evaluation is crucial for advancing ICI therapy in NSCLC brain metastases.
- Further research is needed to establish robust and consistent assessment methods.
- Harmonized evaluation will facilitate better clinical trial design and patient management.
